Table 3 Association of HCC characteristics with genotype distribution of the studied genes

Age

<65

77 (64.2%)

31 (40.3%)

35 (45.5%)

11 (14.3%)

0.1

55 (71.4%)

17 (22.1%)

5 (6.5%)

0.9

>65

43 (35.8%)

26 (60.5%)

13 (30.2%) ^aa

4 (9.3%) ^{aa, bb}

29 (67.4%)

11 (25.6%) ^aa

3 (7.0%) ^{aa, bb}

Sex

Female

30 (25.0%)

13 (43.3%)

14 (46.7%)

3 (10.0%)

0.7

20 (66.7%)

8 (26.7%)

2 (6.7%)

0.9

Male

90 (75.0%)

44 (48.9%)

34 (37.8%) ^a

12 (13.3%) ^{aa, bb}

64 (71.1%)

20 (22.2%) ^aa

6 (6.7%) ^{aa, bb}

Diabetes mellitus (DM)

33 (27.5%)

14 (42.4%)

17 (51.5%)

2 (6.1%) ^{aa, bb}

0.2

25 (75.8%)

7 (21.2%) ^aa

1 (3.0%) ^{aa, bb}

0.6

F.H of HCC

No

117 (97.5%)

55 (47.0%)

48 (41.0%)

14 (12.0%)

0.3

81 (69.2%)

28 (23.9%)

8 (6.8%)

0.5

Yes

3 (2.5%)

2 (66.7%)

0 (0.0%) ^aa

1 (33.3%) ^{aa, bb}

3 (100.0%)

0 (0.0%) ^aa

0 (0.0%) ^aa

ECOG Performance status

0

75 (62.5%)

34 (45.3%)

34 (45.3%)

7 (9.3%) ^{aa, bb}

0.4

51 (68.0%)

17 (22.7%) ^aa

7 (9.3%) ^{aa, bb}

0.8

1

40 (33.3%)

20 (50.0%)

12 (30.0%) ^a

8 (20.0%) ^{aa, b}

29 (72.5%)

10 (25.0%) ^aa

1 (2.5%) ^{aa, bb}

2

4 (3.3%)

2 (50.0%)

2 (50.0%)

0 (0.0%) ^{aa, bb}

3 (75.0%)

1 (25.0%) ^aa

0 (0.0%) ^{aa, bb}

3

1 (0.8%)

1 (100.0%)

0 (0.0%) ^a

0 (0.0%) ^a

1 (100.0%)

0 (0.0%) ^a

0 (0.0%) ^a

Liver: size

Average

111 (92.5%)

52 (46.8%)

45 (40.5%)

14 (12.6%) ^{aa, bb}

0.7

77 (69.4%)

28 (25.2%) ^aa

6 (5.4%) ^{aa, bb}

0.2

Enlarged

8 (6.7%)

5 (62.5%)

2 (25.0%) ^aa

1 (12.5%) ^{aa, b}

6 (75.0%)

0 (0.0%) ^aa

2 (25.0%) ^{aa, bb}

Shrunken

1 (0.8%)

0 (0.0%)

1 (100.0%) ^a

0 (0.0%) ^b

1 (100.0%)

0 (0.0%) ^a

0 (0.0%) ^a

Spleen

Normal

46 (38.3%)

17 (37.0%)

23 (50.0%) ^a

6 (13.0%) ^{aa, bb}

0.3

36 (78.3%)

6 (13.0%) ^aa

4 (8.7%) ^aa

0.08

Average

36 (30.0%)

19 (52.8%)

11 (30.6%) ^aa

6 (16.7%) ^{aa, bb}

21 (58.3%)

14 (38.9%) ^aa

1 (2.8%) ^{aa, bb}

Enlarged

38 (31.7%)

21 (55.3%)

14 (36.8%) ^aa

3 (7.9%) ^{aa, bb}

27 (71.1%)

8 (21.1%) ^aa

3 (7.9%) ^{aa, bb}

Ascites

No

96 (80.0%)

47 (49.0%)

35 (36.5%)

14 (14.6%)

0.2

66 (68.8%)

24 (25.0%)

6 (6.3%)

0.7

Yes

24 (20.0%)

10 (41.7%)

13 (54.2%) ^a

1 (4.2%) ^{aa, bb}

18 (75.0%)

4 (16.7%) ^aa

2 (8.3%) ^{aa, bb}

CHILD Score

A

93 (77.5%)

45 (48.4%)

35 (37.6%) ^a

13 (14.0%) ^{aa, bb}

0.4

64 (68.8%)

22 (23.7%) ^aa

7 (7.5%) ^{aa, bb}

0.8

B

25 (20.8%)

10 (40.0%)

13 (52.0%) ^a

2 (8.0%) ^{aa, bb}

18 (72.0%)

6 (24.0%) ^aa

1 (4.0%) ^{aa, bb}

C

2 (1.7%)

2 (100.0%)

0 (0.0%) ^a

0 (0.0%) ^a

2 (100.0%)

0 (0.0%) ^a

0 (0.0%) ^a

CHILD grade

5.9±1.2

5.88±1.27

5.96±1.11

5.67±0.90

0.7

5.99±1.26

5.71±0.81

5.38±1.06

0.2

No. of F.L

No

2 (1.7%)

1 (50.0%)

1 (50.0%)

0 (0.0%) ^{aa, bb}

0.4

2 (100.0%)

0 (0.0%) ^a

0 (0.0%) ^a

0.9

Single

77 (64.2%)

36 (46.8%)

28 (36.4%) ^a

13 (16.9%) ^{aa, bb}

53 (68.8%)

19 (24.7%) ^aa

5 (6.5%) ^{aa, bb}

Multiple

41 (34.2%)

20 (48.8%)

19 (46.3%)

2 (4.9%) ^{aa, bb}

29 (70.7%)

9 (22.0%) ^aa

3 (7.3%) ^{aa, bb}

F.L site

Right lobe

97 (80.8%)

47 (48.5%)

37 (38.1%) ^a

13 (13.4%) ^{aa, bb}

0.9

67 (69.1%)

24 (24.7%) ^aa

6 (6.2%) ^{aa, bb}

0.3

Left lobe

10 (8.3%)

4 (40.0%)

5 (50.0%) ^a

1 (10.0%) ^{aa, bb}

7 (70.0%)

1 (10.0%) ^aa

2 (20.0%) ^{aa, b}

Both lobes

13 (10.8%)

6 (46.2%)

6 (46.2%)

1 (7.7%) ^{aa, bb}

10 (76.9%)

3 (23.1%) ^aa

0 (0.0%) ^{aa, bb}

F.L size

4.9±3.3

4.83±2.76

4.59±2.35

6.38±6.52

0.1

4.99±3.71

4.88±2.31

4.39±2.15

0.8

P.V

Patent

110 (91.7%)

53 (48.2%)

43 (39.1%)

14 (12.7%) ^{aa, bb}

0.8

76 (69.1%)

26 (23.6%) ^aa

8 (7.3%) ^{aa, bb}

0.6

Thrombosed

10 (8.3%)

4 (40.0%)

5 (50.0%) ^a

1 (10.0%) ^{aa, bb}

8 (80.0%)

2 (20.0%) ^aa

0 (0.0%) ^{aa, b}

Lymph nodes

No

114 (95.0%)

54 (47.4%)

46 (40.4%)

14 (12.3%)

0.9

81 (71.1%)

25 (21.9%)

8 (7.0%)

0.3

Yes

6 (5.0%)

3 (50.0%)

2 (33.3%) ^aa

1 (16.7%) ^{aa, bb}

3 (50.0%)

3 (50.0%)

0 (0.0%) ^{aa, bb}

liver Stiffness

31.8±23.8

31.81±22.92

32.23±24.34

30.44±27.26

0.9

31.5±22.99

32.17±24.77

32.74±30.4

0.9

CAP

223.4±74.4

238.05±70.53

214.49±77.87

198.92±72.46

0.1

218.5±76.23

231.52±61.50

236.75±98.16

0.6

Response to treatment modified RECIST criteria

Complete

73 (60.8%)

32 (43.8%)

33 (45.2%)

8 (11.0%) ^{aa, bb}

0.04*

52 (71.2%)

15 (20.5%) ^aa

6 (8.2%) ^{aa, bb}

0.01*

Partial

13 (10.8%)

8 (61.5%)

3 (23.1%) ^aa

2 (15.4%) ^{aa, b}

10 (76.9%)

2 (15.4%) ^aa

1 (7.7%) ^{aa, b}

Progressive

13 (10.8%)

6 (46.2%)

6 (46.2%)

1 (7.7%) ^{aa, bb}

4 (30.8%)

9 (69.2%) ^aa

0 (0.0%) ^{aa, bb}

Stationary

16 (13.3%)

9 (56.3%)

5 (31.3%) ^aa

2 (12.5%) ^{aa, bb}

14 (87.5%)

1 (6.3%) ^aa

1 (6.3%) ^aa

Clinical decompensation

No

99 (82.5%)

47 (47.5%)

38 (38.4%)

14 (14.1%)

0.4

67 (67.7%)

24 (24.2%)

8 (8.1%)

0.3

Yes

21 (17.5%)

10 (47.6%)

10 (47.6%)

1 (4.8%) ^{aa, bb}

17 (81.0%)

4 (19.0%) ^aa

0 (0.0%)

Developed new lesions or not

No

113 (94.2%)

54 (47.8%)

44 (38.9%)

15 (13.3%)

0.5

80 (70.8%)

26 (23.0%)

7 (6.2%)

0.6

Yes

7 (5.8%)

3 (42.9%)

4 (57.1%) ^a

0 (0.0%) ^{aa, bb}

4 (57.1%)

2 (28.6%) ^aa

1 (14.3%) ^{aa, b}